{"organizations": [], "uuid": "14b65920ea020d5dc69f0bb766545a36b7aeb18f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "//sc.cnbcfm.com/applications/cnbc.com/staticcontent/img/cnbc_logo.gif", "site_section": "http://www.cnbc.com/id/10000027", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/01/03/globe-newswire-crispr-therapeutics-announces-proposed-public-offering-of-common-shares.html", "country": "US", "domain_rank": 767, "title": "CRISPR Therapeutics Announces Proposed Public Offering of Common Shares", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-03T14:15:00.000+02:00", "replies_count": 0, "uuid": "14b65920ea020d5dc69f0bb766545a36b7aeb18f"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/01/03/globe-newswire-crispr-therapeutics-announces-proposed-public-offering-of-common-shares.html", "ord_in_thread": 0, "title": "CRISPR Therapeutics Announces Proposed Public Offering of Common Shares", "locations": [], "entities": {"persons": [], "locations": [{"name": "mass.", "sentiment": "none"}, {"name": "cambridge", "sentiment": "none"}, {"name": "switzerland", "sentiment": "none"}], "organizations": [{"name": "llc", "sentiment": "none"}, {"name": "guggenheim securities", "sentiment": "none"}, {"name": "crispr therapeutics", "sentiment": "none"}, {"name": "barclays capital inc.", "sentiment": "none"}, {"name": "goldman sachs & co", "sentiment": "none"}, {"name": "piper jaffray & co.", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "ZUG, Switzerland and CAMBRIDGE, Mass., Jan. 03, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced that it is commencing an underwritten public offering of $100,000,000 of its common shares. In addition, CRISPR Therapeutics expects to grant the underwriters a 30-day option to purchase up to an additional $15,000,000 of its common shares in connection with the public offering. All of the common shares will be offered by CRISPR Therapeutics.\nGoldman Sachs & Co. LLC, Piper Jaffray & Co. and Barclays Capital Inc. are acting as joint book-running managers for the offering. Guggenheim Securities, LLC is acting as co-manager for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.\nA registration statement on Form S-3 (File No. 333-221491) relating to these securities has been previously filed with and declared effective by the Securities and Exchange Commission (SEC). This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.\nThe offering will be made only by means of a prospectus. A copy of the prospectus supplement relating to the offering will be filed with the SEC and may be obtained, when available, from Goldman, Sachs & Co. LLC by mail at 200 West Street, New York, NY 10282, Attention: Prospectus Department, by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com ; from Piper Jaffray & Co., Attn: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924, or by email at prospectus@pjc.com ; or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (888) 603-5847 or by email at Barclaysprospectus@broadridge.com.\nAbout CRISPR Therapeutics\nCRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts.\nCautionary Note Regarding Forward-Looking Statements\nThis press release contains within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding CRISPR Therapeutics’ anticipated public offering. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify , although not all contain these identifying words. Any in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ expressed or implied by any contained in this press release, including, without limitation, uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in CRISPR Therapeutics’ Annual Report on Form 10-K for the year ended December 31, 2016, as filed with the SEC on March 10, 2017, the prospectus supplement related to the public offering and other filings that CRISPR Therapeutics may make with the SEC in the future. Any contained in this press release represent CRISPR Therapeutics’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. CRISPR Therapeutics explicitly disclaims any obligation to update any\nCRISPR Therapeutics\nInvestors:\nChris Erdman\n617-307-7227\nchris.erdman@crisprtx.com\nor\nChris Brinzey\nWestwicke Partners for CRISPR Therapeutics\n339-970-2843\nchris.brinzey@westwicke.com\nMEDIA CONTACT:\nJennifer Paganelli\nW2O Group for CRISPR Therapeutics\n347-658-8290\njpaganelli@w2ogroup.com\nSource:CRISPR Therapeutics AG", "external_links": ["https://www.globenewswire.com/Tracker?data=eb9jhA98cP4VqfTfZLQNlQYgBrxTYg3sb6czPNxIPq5h4snMYla-5U8CQNZcEsbRAw42qPi9YZyA4UKMyns6BJ4VNWFJjR1ZCojA3xwNES8=", "https://www.globenewswire.com/NewsRoom/AttachmentNg/01d77e78-cd3b-4a54-8423-b38667705fe9", "https://www.globenewswire.com/Tracker?data=eb9jhA98cP4VqfTfZLQNlVl-5YBlWAH9nxyslWcydOld4QdXbyLxU8xcuyvQW-TujoyQwMicVXqbnfDmS9cSOez0vY1yjBB2vyssTHAPhev2USm8YQGeQdBZAfDb1eUZ", "https://www.globenewswire.com/Tracker?data=W1cqPTpTr-7lZJ6EXQ5KCBuedgePa3avBn4t6POBEr1st-Q2KsdboS6OO_LUmhA1G9kUO3FXNTEwlVVQjo_u-9L71u7WlXJrcB_qyVFB43o="], "published": "2018-01-03T14:15:00.000+02:00", "crawled": "2018-01-03T13:56:59.027+02:00", "highlightTitle": ""}